Ischemia-modified albumin (IMA) and dynamic thiol-disulfide homeostasis in patients with postherpetic neuralgia

Basit Öğe Kaydı
dc.contributor.authorArican, Sule
dc.contributor.authorHacibeyoglu, Gulcin
dc.contributor.authorUlukaya, Sinan Oguzhan
dc.contributor.authorAvcioglu, Gamze
dc.contributor.authorReisli, Ruhiye
dc.contributor.authorUzun, Sema Tuncer
dc.contributor.authorErel, Ozcan
dc.date.accessioned2024-02-23T14:31:53Z
dc.date.available2024-02-23T14:31:53Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractBackground: Ischemia-modified albumin (IMA) is an isotype of albumin that increases under oxidative stress, and plasma thiols are main defense mechanisms against oxidative stress. The objective of this study was to investigate thiol-disulfide homeostasis and serum IMA levels in postherpetic neuralgia (PHN) patients. Methods: A total of 29 PHN patients and 30 healthy controls were included in the study. Serum total and native thiol concentrations and serum disulfide concentration were measured using the method described by Erel and Neselioglu. The albumin cobalt binding test was used to measure serum IMA levels. Results: Serum IMA levels were 1.21 +/- 0.58 AU and 0.75 +/- 0.09 AU in the PHN and control groups, respectively (p <0.001). Serum total thiol concentrations were found to be 421.62 +/- 90.28 mu mol/L and 598.36 +/- 73.63 mu mol/L in the PHN and control groups, respectively (p <0.001). Serum native thiol concentrations were found to be 365.75 +/- 92.07 mu mol/L and 531.90 +/- 72.9 mu mol/L in the PHN and control groups, respectively (p < 0.001). Serum disulfide concentrations were found to be 33.23 +/- 5.33 mu mol/L and 27.93 +/- 7.81 mu mol/L in the PHN and control groups, respectively (p= 0.003). The native thiol/total thiol ratio was significantly lower, and the disulfide/total thiol and disulfide/native thiol ratios were significantly higher in the PHN group compared to the controls. Conclusions: IMA levels are high and dynamic thiol/disulfide homeostasis is disrupted in PHN patients.en_US
dc.identifier.doi10.1515/labmed-2018-0211
dc.identifier.endpage263en_US
dc.identifier.issn2567-9430
dc.identifier.issn2567-9449
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-85072637199en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage257en_US
dc.identifier.urihttps://doi.org/10.1515/labmed-2018-0211
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15391
dc.identifier.volume43en_US
dc.identifier.wosWOS:000489533000005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWalter De Gruyter Gmbhen_US
dc.relation.ispartofJournal Of Laboratory Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIschemia-Modified Albuminen_US
dc.subjectOxidative Stressen_US
dc.subjectPostherpetic Neuralgiaen_US
dc.subjectThiol/Disulfideen_US
dc.titleIschemia-modified albumin (IMA) and dynamic thiol-disulfide homeostasis in patients with postherpetic neuralgiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu